Millennium Laboratories has announced that it has initiated a first-of-its-kind, large-scale prospective clinical outcomes study of its pharmacogenetic test. The longitudinal study will evaluate the relationship of genetic variability and clinical pain management outcomes.
Encompassing more than 30 practice sites nationally, it is designed to evaluate the relationship between cytochrome P-450 (CYP) genotype, as determined by Millennium Pharmacogenetic Testing (PGT), and clinical outcomes including level of analgesia, functional status, and clinically significant opioid-related adverse events. The study will also seek to assess the benefit to prescribers of pharmacogenetic information arising from Millennium PGT and characterize any corresponding changes in prescribing patterns. Up to 1,250 subjects meeting the study entry criteria will be enrolled into the initial, cross-sectional phase. Subjects categorized by the test as poor or ultra-rapid metabolizers will continue into the longitudinal phase of the study. Learn more about Millennium Laboratories.
